Skye Bioscience, Inc. (SKYE) stock
SKYENasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.03+0.03 (+3.00%)
Close on Nov 18, 2026Market cap $36.48MP/E –Yield –
Skye Bioscience free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Skye Bioscience's free cash flow for the twelve months ending Jun 30, 2026 was -$38.81M. For fiscal 2025 it was -$43.07M. The highest annual figure on record is -$63.61K in fiscal 2013.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$43.07M | – |
| FY2024 | Dec 31, 2024 | -$26.84M | – |
| FY2023 | Dec 31, 2023 | -$13.96M | – |
| FY2022 | Dec 31, 2022 | -$12.77M | – |
| FY2021 | Dec 31, 2021 | -$6.57M | – |
| FY2020 | Dec 31, 2020 | -$6.06M | – |
| FY2018 | Dec 31, 2018 | -$3.95M | – |
| FY2017 | Dec 31, 2017 | -$3.35M | – |
| FY2016 | Dec 31, 2016 | -$3.56M | – |
| FY2015 | Dec 31, 2015 | -$3.73M | – |
| FY2013 | Oct 31, 2013 | -$63.61K | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$7.12M | – |
| Q1 FY2026 | Mar 31, 2026 | -$8.56M | – |
| Q4 FY2025 | Dec 31, 2025 | -$9.77M | – |
| Q3 FY2025 | Sep 30, 2025 | -$13.36M | – |
| Q2 FY2025 | Jun 30, 2025 | -$10.75M | – |
| Q1 FY2025 | Mar 31, 2025 | -$9.19M | – |
| Q4 FY2024 | Dec 31, 2024 | -$8.22M | – |
| Q3 FY2024 | Sep 30, 2024 | -$6.78M | – |
| Q2 FY2024 | Jun 30, 2024 | -$7.13M | – |
| Q1 FY2024 | Mar 31, 2024 | -$4.71M | – |
| Q4 FY2023 | Dec 31, 2023 | -$3.85M | – |
| Q3 FY2023 | Sep 30, 2023 | -$4.06M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.99M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.06M | – |
| Q4 FY2022 | Dec 31, 2022 | -$4.88M | – |
| Q3 FY2022 | Sep 30, 2022 | -$2.07M | – |
| Q2 FY2022 | Jun 30, 2022 | -$2.90M | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.92M | – |
| Q4 FY2021 | Dec 31, 2021 | -$2.02M | – |
| Q3 FY2021 | Sep 30, 2021 | -$1.51M | – |
| Q2 FY2021 | Jun 30, 2021 | -$1.67M | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.36M | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.79M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.97M | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.03M | – |
| Q1 FY2020 | Mar 31, 2020 | -$1.27M | – |
| Q4 FY2018 | Dec 31, 2018 | -$1.01M | – |
| Q3 FY2018 | Sep 30, 2018 | -$816.28K | – |
| Q2 FY2018 | Jun 30, 2018 | -$1.06M | – |
| Q1 FY2018 | Mar 31, 2018 | -$1.05M | – |
| Q4 FY2016 | Dec 31, 2016 | -$662.78K | – |
| Q3 FY2016 | Sep 30, 2016 | -$511.73K | – |
See a number that looks wrong?